Lotus Eye Hospital Promoter Sangeetha Sundaramoorthy Acquires Additional Stake Under SEBI Exemption

1 min read Updated on 02 Mar 2026, 04:41 PM

Reviewed by

Radhika SScanX News Team

Overview

Sangeetha Sundaramoorthy acquired 14,28,571 shares of Lotus Eye Hospital and Institute Limited from Kavetha Sundaramoorthy at Rs.70 per share, increasing her stake from 28.1391% to 35.0084%. The inter-promoter transfer, completed on February 27, 2026, was executed under SEBI regulation exemption and properly disclosed to BSE and NSE. This transaction represents 6.8693% of the company's diluted share capital and demonstrates consolidation within the promoter group of the eye care services company.

*this image is generated using AI for illustrative purposes only.

Lotus Eye Hospital and Institute Limited has witnessed a significant inter-promoter share transfer, with Sangeetha Sundaramoorthy acquiring additional equity stake from Kavetha Sundaramoorthy under SEBI takeover regulation exemptions.

Transaction Details

The acquisition involved 14,28,571 shares purchased at Rs.70 per share through a share purchase agreement executed on June 2, 2025. The transaction was completed on February 27, 2026, representing 6.8693% of the company's diluted share capital.

Transaction Parameter:	Details
Shares Acquired:	14,28,571
Price per Share:	Rs.70
Transaction Date:	February 27, 2026
Agreement Date:	June 2, 2025
Percentage of Capital:	6.8693%

Regulatory Compliance

The transaction was executed under Regulation 10(1)(a)(ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which provides exemption from making an open offer for inter-promoter transfers. Sangeetha Sundaramoorthy filed the required disclosure with BSE and NSE on January 27, 2026, adhering to the timeline specified under Regulation 10(5).

Shareholding Changes

The inter-promoter transfer resulted in significant changes to the ownership structure between the two promoters:

Stakeholder:	Pre-Transaction Shares	Pre-Transaction %	Post-Transaction Shares	Post-Transaction %
Sangeetha Sundaramoorthy:	58,51,901	28.1391%	72,80,472	35.0084%
Kavetha Sundaramoorthy:	19,99,564	9.6149%	5,70,993	2.7456%

Market Listing

Lotus Eye Hospital and Institute Limited shares are listed on both BSE and NSE. The company operates in the healthcare sector, specifically focusing on eye care services and related medical treatments.

Regulatory Framework

The transaction falls under the exemption category that allows promoters to transfer shares among themselves without triggering mandatory open offer requirements, provided proper disclosures are made to stock exchanges within stipulated timelines.

Historical Stock Returns for Lotus Eye Hospital

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.30%	-8.38%	-16.07%	+3.99%	+80.21%	+209.81%

Lotus Eye Hospital

View Company Insights

View All News

Lotus Eye Hospital Reports Q3FY26 Net Loss Despite Revenue Growth, Appoints New Company Secretary

2 min read Updated on 11 Feb 2026, 06:55 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Overview

Lotus Eye Hospital And Institute Limited announced mixed Q3FY26 results with revenue growth of 10.64% to ₹1,354.96 lakhs but reported a net loss of ₹26.07 lakhs. The nine-month performance remained positive with ₹39.99 lakhs profit and 5.40% revenue growth. The company also appointed Mr. Prathish S as Company Secretary & Compliance Officer effective February 13, 2026.

*this image is generated using AI for illustrative purposes only.

Lotus eye hospital And Institute Limited announced its unaudited standalone financial results for the quarter ended December 31, 2025, revealing mixed performance with quarterly losses offset by positive nine-month results. The eye care specialist also made a key management appointment during its Board meeting held on February 11, 2026.

Financial Performance Overview

The company's Q3FY26 performance showed contrasting trends between revenue growth and profitability. While total income increased to ₹1,378.51 lakhs from ₹1,246.77 lakhs in the corresponding quarter of the previous year, the company reported a net loss of ₹26.07 lakhs compared to a loss of ₹23.91 lakhs in Q3FY25.

Financial Metric:	Q3FY26	Q3FY25	Change
Revenue from Operations:	₹1,354.96 lakhs	₹1,224.69 lakhs	+10.64%
Total Income:	₹1,378.51 lakhs	₹1,246.77 lakhs	+10.57%
Net Loss:	₹26.07 lakhs	₹23.91 lakhs	-9.03%
Basic EPS:	₹(0.13)	₹(0.11)	-

Nine-Month Performance Remains Positive

Despite the quarterly setback, the company's nine-month performance for the period ending December 31, 2025, demonstrated resilience with sustained profitability and revenue growth.

Parameter:	Nine Months FY26	Nine Months FY25	Growth
Revenue from Operations:	₹4,010.49 lakhs	₹3,805.00 lakhs	+5.40%
Net Profit:	₹39.99 lakhs	₹48.69 lakhs	-17.85%
Total Comprehensive Income:	₹33.49 lakhs	₹44.36 lakhs	-24.50%
Basic EPS:	₹0.19	₹0.23	-17.39%

Expense Analysis and Operational Metrics

The company's total expenses for Q3FY26 increased to ₹1,416.07 lakhs from ₹1,289.12 lakhs in the previous year, representing a 9.85% rise. Key expense categories showed varying trends with employee benefit expenses rising to ₹313.76 lakhs from ₹295.62 lakhs, service expenses increasing significantly to ₹276.74 lakhs from ₹238.98 lakhs, and finance costs more than doubling to ₹28.54 lakhs from ₹12.63 lakhs. However, depreciation expenses decreased to ₹98.24 lakhs from ₹130.69 lakhs.

Key Management Appointment

The Board of Directors approved the appointment of Mr. Prathish S as Company Secretary & Compliance Officer, effective February 13, 2026. Mr. Prathish S is an Associate Member of the Institute of Company Secretaries of India with membership number A73669.

Appointment Details:	Information
Name:	Mr. Prathish S
Position:	Company Secretary & Compliance Officer
Effective Date:	February 13, 2026
Qualification:	Associate Member, ICSI
Membership Number:	A73669

Company Operations and Outlook

Lotus Eye Hospital operates exclusively in the eye care segment, providing specialized sales and services. The company maintains a network of facilities across Tamil Nadu and Kerala, with locations in Coimbatore, Salem, Tirupur, Kochi, Karur, and Gobichettipalayam. The paid-up equity share capital remained stable at ₹2,079.63 lakhs with a face value of ₹10 per share. The financial results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditors conducting a limited review of the quarterly results.

Historical Stock Returns for Lotus Eye Hospital